AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20843990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy
Number of subjects: 186
Study 20843990 — intervention group
Group type: COMPARATOR
Intervention: Current combined antiretroviral treatment (cART)
Number of subjects: 186
Study 20843990 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy (with treatment intensification)
Number of subjects: 186
Study 19042197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment Readiness Scale (PRS)
Number of subjects: 367
Study 19042197 — intervention group
Group type: COMPARATOR
Intervention: Texas Christian University‐Treatment Motivation Assessment (TCU‐TMA)
Number of subjects: 367
Study 16029399 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC 0.25 mg.kg(‐1)
Number of subjects: 42
Study 16029399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 13129880 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and foldable intraocular lens (IOL) implantation
Number of subjects: 21
Study 10499748 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL 1.5% lidocaine plus epinephrine 15 microg (1/200,000)
Number of subjects: 40
Study 10499748 — intervention group
Group type: COMPARATOR
Intervention: 3 mL normal saline
Number of subjects: 40
Study 8711613 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision Harmonic Scalpel LCS (LCS)
Number of subjects: 20
Study 8711613 — intervention group
Group type: COMPARATOR
Intervention: Multifire clip applier (MCA) and sharp division
Number of subjects: 20
Study 1800468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl, 5 micrograms/mL
Number of subjects: 15
Study 1800468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl, 5 micrograms/mL with 0.75% solution of lidocaine
Number of subjects: 15
Study 1800468 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl, 5 micrograms/mL with 1.0% solution of lidocaine
Number of subjects: 15
Study 1800468 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 15
Study 6344982 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin-CCNU
Number of subjects: 35
Study 6344982 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-CCNU-Vincristine (VCR)
Number of subjects: 35
Study 31007108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicitis agents screening using multiplex PCR
Number of subjects: 133
Study 31007108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervicitis presence
Number of subjects: 133
Study 30382904 — intervention group
Group type: EXPERIMENTAL
Intervention: Wei nasal jet tube (WNJT)
Number of subjects: 308
Study 30382904 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 308
Study 27578574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training followed by non-invasive positive pressure ventilation (IMT-NPPV group)
Number of subjects: 88
Study 27578574 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training only (IMT group)
Number of subjects: 88
Study 27578574 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation only (NPPV group)
Number of subjects: 88
Study 27578574 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy (control group)
Number of subjects: 88
Study 24963566 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day event-triggered recorder (intervention group)
Number of subjects: 572
Study 24963566 — intervention group
Group type: COMPARATOR
Intervention: Conventional 24-hour monitor (control group)
Number of subjects: 572
Study 21916811 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG+Doppler
Number of subjects: 256
Study 21916811 — intervention group
Group type: COMPARATOR
Intervention: CTG
Number of subjects: 256
Study 18556619 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced patient-based partner notification
Number of subjects: 600
Study 18556619 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 600
Study 17650791 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 7422
Study 17650791 — intervention group
Group type: COMPARATOR
Intervention: Previous RCTs (1980-1998)
Number of subjects: 7422
Study 15200542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 80
Study 15200542 — intervention group
Group type: COMPARATOR
Intervention: Bonfils intubation fibrescope
Number of subjects: 80
Study 12217071 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training
Number of subjects: 40
Study 12217071 — intervention group
Group type: COMPARATOR
Intervention: Flexibility program
Number of subjects: 40
Study 9690805 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning subcutaneous administration of 5000 IU dalteparin
Number of subjects: 17
Study 9690805 — intervention group
Group type: COMPARATOR
Intervention: Evening subcutaneous administration of 5000 IU dalteparin
Number of subjects: 17
Study 9690805 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 5000 IU dalteparin
Number of subjects: 17
Study 9690805 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of 2500 IU dalteparin
Number of subjects: 17
Study 8088043 — intervention group
Group type: EXPERIMENTAL
Intervention: Erect position (sitting or ambulant)
Number of subjects: 105
Study 8088043 — intervention group
Group type: COMPARATOR
Intervention: Decubitus position (right side down)
Number of subjects: 105
Study 2758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy and axillary clearance (40 women)
Number of subjects: 94
Study 2758260 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy and axillary sampling (54 women)
Number of subjects: 94
Study 2758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (28 women with axillary nodal metastasis)
Number of subjects: 94
Study 2758260 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant radiotherapy (26 women without axillary nodal metastasis)
Number of subjects: 94
Study 2758260 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 94
Study 796939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg daily for 4 weeks
Number of subjects: 20
Study 796939 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg daily for 4 weeks
Number of subjects: 20
Study 31444669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency sonophoresis of Chinese medicine (LFS/CM) combined with intrapleural IL-2
Number of subjects: 110
Study 31444669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency sonophoresis of Chinese medicine (LFS/CM)
Number of subjects: 110
Study 31444669 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of IL-2 (control group)
Number of subjects: 110
Study 30528639 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical fatigability (≥ 15)
Number of subjects: 29
Study 30528639 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mental fatigability (≥ 13)
Number of subjects: 29
Study 30528639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both higher physical and mental fatigability
Number of subjects: 29
Study 28279950 — intervention group
Group type: EXPERIMENTAL
Intervention: InsuOnline electronic game intervention
Number of subjects: 134
Study 28279950 — intervention group
Group type: COMPARATOR
Intervention: Traditional CME session
Number of subjects: 134
Study 25919754 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 199
Study 25919754 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 199
Study 22961727 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol phenylbutyrate
Number of subjects: 65
Study 22961727 — intervention group
Group type: COMPARATOR
Intervention: Sodium phenylbutyrate (NaPBA)
Number of subjects: 65
Study 21402981 — intervention group
Group type: EXPERIMENTAL
Intervention: Order of IOP measurement starting with right eye
Number of subjects: 105
Study 21402981 — intervention group
Group type: COMPARATOR
Intervention: Order of IOP measurement starting with left eye
Number of subjects: 105
Study 21402981 — intervention group
Group type: EXPERIMENTAL
Intervention: First visit measurements
Number of subjects: 105
Study 21402981 — intervention group
Group type: EXPERIMENTAL
Intervention: Right eye measurements
Number of subjects: 105
Study 21402981 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular squeezing
Number of subjects: 105
Study 19277472 — intervention group
Group type: EXPERIMENTAL
Intervention: KKS Network support for clinical trials
Number of subjects: 0
Study 17886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with ACE‐i
Number of subjects: 2100
Study 17886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with ARB
Number of subjects: 2100
Study 17886213 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with ACE‐i + ARB
Number of subjects: 2100
Study 14996515 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine hydrochloride 0.05% ophthalmic solution, 1 drop/eye BID for 8 weeks
Number of subjects: 298
Study 14996515 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine hydrochloride 0.05% ophthalmic suspension, 1 drop/eye BID for 8 weeks
Number of subjects: 298
Study 14996515 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of epinastine, 1 drop/eye BID for 8 weeks
Number of subjects: 298
Study 11795349 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study 11795349 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 0
Study 9043840 — intervention group
Group type: EXPERIMENTAL
Intervention: Antianginal therapy (nitrates and calcium antagonists)
Number of subjects: 26
Study 7884660 — intervention group
Group type: EXPERIMENTAL
Intervention: TY‐11345 (40 mg single dose)
Number of subjects: 2
Study 7884660 — intervention group
Group type: EXPERIMENTAL
Intervention: TY‐11345 (20 mg single dose)
Number of subjects: 2
Study 7884660 — intervention group
Group type: EXPERIMENTAL
Intervention: TY‐11345 (60 mg repeated dose)
Number of subjects: 2
Study 7884660 — intervention group
Group type: EXPERIMENTAL
Intervention: TY‐11345 (40 mg single dose with food)
Number of subjects: 2
Study 7884660 — intervention group
Group type: EXPERIMENTAL
Intervention: TY‐11345 (20, 40, and 80 mg single doses)
Number of subjects: 2
Study 7884660 — intervention group
Group type: EXPERIMENTAL
Intervention: TY‐11345 (all doses)
Number of subjects: 2
Study 3124674 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine twice daily
Number of subjects: 215
Study 3124674 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg chlorpheniramine three times daily
Number of subjects: 215
Study 3124674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 30176758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine misoprostol (400 mg) added to oxytocin
Number of subjects: 300
Study 30176758 — intervention group
Group type: COMPARATOR
Intervention: Routine oxytocin alone
Number of subjects: 300
Study 30782151 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium Observation Screening Scale (DOS)
Number of subjects: 193
Study 28596192 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 104
Study 28596192 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 104
Study 28596192 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation and General Anesthesia
Number of subjects: 104
Study 26300016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 0.3 g.kg(‐1) body weight
Number of subjects: 15
Study 26300016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose)
Number of subjects: 15
Study 26300016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 15
Study 23273683 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural infusion (PERI group)
Number of subjects: 60
Study 23273683 — intervention group
Group type: COMPARATOR
Intervention: Continuous local wound infiltration (LOC group)
Number of subjects: 60
Study 21664026 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based educational program (4 simulation scenarios in a 6h education session)
Number of subjects: 31
Study 21664026 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 31
Study 18536698 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg
Number of subjects: 23
Study 18536698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16849754 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g EPA
Number of subjects: 518
Study 16849754 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g EPA
Number of subjects: 518
Study 16849754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 12845488 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg/day orally for 5 days
Number of subjects: 55
Study 12845488 — intervention group
Group type: COMPARATOR
Intervention: Low-iodine diet for 14 days
Number of subjects: 55
Study 12845488 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 55
Study 12845488 — intervention group
Group type: COMPARATOR
Intervention: Low-iodine diet
Number of subjects: 55
Study 10759443 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure (BiPAP) at 15 cmH2O Phigh and 5 cmH2O Plow
Number of subjects: 21
Study 10759443 — intervention group
Group type: COMPARATOR
Intervention: Pressure support (PS) at 15 cmH2O
Number of subjects: 21
Study 10759443 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic positive airway pressure (BiPAP) during Plow phases
Number of subjects: 21
Study 10759443 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) at 5 cmH2O
Number of subjects: 21
Study 8810812 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCCP (Percutaneous transhepatic cholecyst puncture)
Number of subjects: 35
Study 8810812 — intervention group
Group type: COMPARATOR
Intervention: PTCCD (Percutaneous transhepatic cholecyst drainage)
Number of subjects: 35
Study 8810812 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (antibiotics administration)
Number of subjects: 35
Study 1419940 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms sufentanil
Number of subjects: 37
Study 1419940 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms sufentanil
Number of subjects: 37
Study 1419940 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms sufentanil
Number of subjects: 37
Study 1419940 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 37
Study 1419940 — intervention group
Group type: EXPERIMENTAL
Intervention: All sufentanil groups
Number of subjects: 37
Study 1419940 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 37
Study 3907376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 0
Study 30939537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogens (o-CEE)
Number of subjects: 727
Study 30939537 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17Î²-estradiol (t-E2)
Number of subjects: 727
Study 30939537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 30341117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single FMT dose
Number of subjects: 30
Study 30341117 — intervention group
Group type: EXPERIMENTAL
Intervention: Five daily FMT doses
Number of subjects: 30
Study 30341117 — intervention group
Group type: COMPARATOR
Intervention: Control (no FMT dose)
Number of subjects: 30
Study 27150723 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (one face-to-face contact and one phone contact with the interventionist)
Number of subjects: 140
Study 27150723 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 140
Study 24534225 — intervention group
Group type: EXPERIMENTAL
Intervention: NPSRH
Number of subjects: 83
Study 24534225 — intervention group
Group type: COMPARATOR
Intervention: CRH
Number of subjects: 83
Study 22966104 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach intervention (direct mailing of FOBT kits and colorectal cancer fact sheet)
Number of subjects: 202
Study 22966104 — intervention group
Group type: COMPARATOR
Intervention: Usual care (referral for screening during clinician visits)
Number of subjects: 202
Study 20560847 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based clinician-assisted cognitive behavioural treatment program (the Panic program)
Number of subjects: 59
Study 20560847 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 59
Study 16900557 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic treatments
Number of subjects: 0
Study 16900557 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy or placebo
Number of subjects: 0
Study 16195955 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 75
Study 16195955 — intervention group
Group type: COMPARATOR
Intervention: Drug-free Baseline session
Number of subjects: 75
Study 16195955 — intervention group
Group type: EXPERIMENTAL
Intervention: Later sessions (regardless of drug condition)
Number of subjects: 75
Study 16195955 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (for Combined subtype)
Number of subjects: 75
Study 11824858 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 80
Study 11824858 — intervention group
Group type: COMPARATOR
Intervention: Control (no antihypertensive therapy)
Number of subjects: 80
Study 10511835 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based intervention
Number of subjects: 2109
Study 10511835 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-based intervention
Number of subjects: 2109
Study 10511835 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2109
Study 8523056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2a (rIFN alpha-2a) at 3 million units (MU)/m2 subcutaneously three times per week, escalated to 9 MU/m2 as tolerated.
Number of subjects: 171
Study 8523056 — intervention group
Group type: COMPARATOR
Intervention: Observation alone (control group).
Number of subjects: 171
Study 8523056 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2a (rIFN alpha-2a).
Number of subjects: 171
Study 2287905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 179
Study 2287905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephradine
Number of subjects: 179
Study 2287905 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 179
Study 7317249 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms kg‐1
Number of subjects: 50
Study 7317249 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate 10 micrograms kg‐1
Number of subjects: 50
Study 30547704 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (Transcatheter Aortic Valve Implantation)
Number of subjects: 0
Study 30547704 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 30170643 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 27
Study 30170643 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond diet
Number of subjects: 27
Study 26940027 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECAP-A
Number of subjects: 0
Study 26940027 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3 L
Number of subjects: 0
Study 24738803 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (n = 62)
Number of subjects: 115
Study 24738803 — intervention group
Group type: COMPARATOR
Intervention: Epidural (n = 53)
Number of subjects: 115
Study 22409383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 158
Study 22409383 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 158
Study 22409383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 19155827 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline washout
Number of subjects: 73
Study 19155827 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available acidic washout solution (Contisol)
Number of subjects: 73
Study 19155827 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no washout)
Number of subjects: 73
Study 17999011 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training of non-operated limb for 3 weeks
Number of subjects: 62
Study 17999011 — intervention group
Group type: COMPARATOR
Intervention: Regular-intensity strength training of non-operated limb for 3 weeks
Number of subjects: 62
Study 15021311 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alfa-2b 3 mIU daily plus RBV 800 mg/d
Number of subjects: 180
Study 15021311 — intervention group
Group type: COMPARATOR
Intervention: IFN alfa-2b 3 mIU thrice weekly plus RBV 800 mg/d
Number of subjects: 180
Study 11825138 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support program
Number of subjects: 219
Study 11825138 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 219
Study 10729968 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 100
Study 10729968 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 100
Study 10729968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 100
Study 10729968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8835361 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL 64170XX 0.5% enema
Number of subjects: 23
Study 8835361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2257959 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% naproxen gel
Number of subjects: 30
Study 2257959 — intervention group
Group type: COMPARATOR
Intervention: 10% ketoprofen gel
Number of subjects: 30